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In the last five years, evidence has accumulated confirming
the superiority of implantable cardioverter-defibrillator
(ICD) therapy compared to antiarrhythmic drug therapy for
prevention of sudden death (1,2). Clinical trials, with rare
exception, have established mortality benefits of ICD ther-
apy in a variety of patients at risk for sudden arrhythmic
death. Just as clinicians have begun to incorporate this new
device therapy into everyday medical practice, recent reports
and analyses of existing databases have complicated this
relatively straightforward perception. These concepts have
taken future development of ICD therapy in several new
directions.
Implantable defibrillators and quality-of-life. In contrast
to mortality end points, the benefits of ICD therapy with
respect to patient morbidity and quality-of-life vis-a-vis
drug therapy have always been less convincing. In these
trials, device-related complications requiring treatment have
ranged from 6% to 16% (1,3). While quality-of-life mea-
sures show some areas of patient benefit, this is not apparent
in other areas of daily life. Despite patient education and
in-hospital experience, the delivery of programmed shock
therapy is rarely welcomed by its recipient. Psychologic
profiles of ICD recipients regularly identify a fear of ICD
shocks, and an association between multiple or “cluster”
shock experiences and mood disorders (4,5). Limitations in
physical activity, and even temporary suspension of driving
privileges, for arrhythmia recurrences after device implant
are generally resented, particularly by active patients. It is
therefore not surprising that a variety of technologic and
research initiatives have been designed to alleviate these
concerns.
See page 824
In this issue of the Journal, Higgins and coworkers (6)
report the initial results of a randomized comparison of
atrial synchronous biventricular pacing with support biven-
tricular pacing on the need for antitachycardia therapy in
patients with recently implanted cardioverter-defibrillators
using a crossover study design. They report a decline in the
number of patients receiving antitachycardia interventions
(pacing or shocks) with atrial synchronous biventricular
pacing during three-month observation periods in each
mode. These findings are intriguing, clinically novel and
merit careful consideration. The potential clinical contribu-
tion of their findings is to extend the capability of pacing
techniques in reducing undesirable effects of antitachycardia
interventions, particularly shock therapy delivery in ICD
recipients.
Nearly a decade ago, the ability of antitachycardia pacing
to diminish the need for shock delivery for ventricular
tachycardia (VT) events by 89% was documented by pro-
spective study (3). However, a proportion of VT events,
particularly faster episodes and ventricular fibrillation (VF),
remained amenable only to shock delivery. The VT epi-
sodes, particularly those with rates .180 to 200 beats/min,
have been tested with low-energy transvenous shocks (7,8).
Even biphasic waveforms have required initial shock volt-
ages .300 V or energies of 5 J with current transvenous lead
systems to achieve acceptable efficacy ($80% initial shock
success). While these data have produced rational two- or
three-zone VT/VF detection and programming algorithms
(9), shock delivery with its attendant patient discomfort has
remained the initial therapy in at least two of the three
potential arrhythmia detection zones (9). Most shocks are
now delivered in the nonsyncopal state, without impairment
of consciousness and often occurring during the course of
important daily activities of life (10).
Can electrical therapies reduce arrhythmic events? Al-
ternative strategies are being sought to reduce shock expo-
sure. The “holy grail” of electrical therapy for tachyarrhyth-
mia prevention has been prevention of arrhythmia onset by
electrical techniques. Strategies to this end have included
dual-site stimulation to prevent reentrant ventricular
rhythms (11). Stimulation performed at two disparate sites
in experimental studies can alter the nature and extent of the
arc of conduction block or advance activation in other
regions. This can prevent initiation or maintenance of a
reentrant tachycardia (11). Widespread clinical use of this
technique has actually been performed in patients with atrial
fibrillation (12). Contact and noncontact mapping studies
have demonstrated that dual-site atrial stimulation can
advance biatrial activation and prevent initiation of atrial
fibrillation in patients with refractory atrial fibrillation
(13–15). The technique has been clinically validated in large
observational trials for prevention of drug-refractory atrial
fibrillation in a “hybrid” therapy approach. Monotherapy
with conventional single-site pacing has been less successful
in arrhythmia prevention, particularly in patients with
refractory conditions (16). For dual-site ventricular pacing,
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the relative location of the stimulation sites to the regions
critical to triggers or reentry, as well as the timing of the two
stimuli relative to each other, critically influences the extent
of electrophysiologic effects (11).
Clinical application of dual-site ventricular stimulation
for arrhythmia prevention has hitherto been lacking. In this
report, Higgins and coworkers (6) have performed a retro-
spective analysis of event rates with biventricular stimula-
tion, performed largely for hemodynamic benefit in an ICD
population at high risk for recurrent VT or VF.
Angiotensin-converting enzyme inhibitor therapy, with its
favorable effects on ventricular hemodynamics and remod-
eling, has been associated with reduced risk of sudden
arrhythmic death (17). Biventricular pacing clearly alters
atrioventricular filling relationships, especially on the left
side with potential hemodynamic advantage, although no
data to this effect are presented in this analysis. Thus, the
role of improved ventricular function, reduced left ventric-
ular volumes and secondary electrophysiologic effects on
triggers or ventricular arrhythmia substrate cannot be judged
from their report.
The extent of electrophysiologic impact also cannot be
evaluated from the end points presented. The effects of
dual-site pacing on ventricular activation patterns and du-
ration can vary in populations with and without intraven-
tricular conduction defects. In atrial fibrillation populations,
global P-wave duration decreases by 10% to 25%, as does
regional activation times (13). While it has been demon-
strated that QRS durations do decrease with effective
biventricular stimulation in patients with intraventricular
conduction defects, these data are not presented (18).
Furthermore, the magnitude and location of these effects are
also not available from this study.
The site of ventricular stimulation is an important vari-
able. Over two decades ago, the relationship between the
site of origin of a ventricular contraction and its mechanical
efficacy in stroke output was reported (19). More recently,
Blanc and coworkers (20) showed superiority of left ven-
tricular pacing and biventricular pacing over right ventric-
ular apical or outflow tract pacing with respect to hemody-
namic variables such as wedge pressure, cardiac index and
systemic blood pressure during short-term studies. Left
ventricular pacing was similar to biventricular pacing. Apical
ventricular stimulation, particularly if performed simulta-
neously from the right and left ventricle, produces more
effective hemodynamic results than basal ventricular stimu-
lation (21). The difference between epicardial left ventricu-
lar pacing in this report and endocardial stimulation has not
been well studied. A recent report on the feasibility of
chronic endocardial left ventricular stimulation may well
stimulate this discussion (22). It is also worthy of note that
there may not be concordance between optimal ventricular
electrical resynchronization and hemodynamic results.
Thus, an activation sequence that may suppress VT/VF
onset may not necessarily have the preferred hemodynamic
impact.
There are significant methodologic issues in any retro-
spective analysis, and this clinical trial is no exception. In
atrial fibrillation populations, the degree of pacing achieved
influences suppression of triggers and atrial fibrillation
recurrences (23). No quantitative data are available as to the
extent of biventricular pacing achieved in the two groups.
The observation periods for arrhythmia prevention were
relatively brief (three months) in each mode. While the first
six months clearly are associated with the highest event
rates, there is an exponential decline over the first year (24).
While randomization clearly addresses some of the short-
term results, the long-term benefits of biventricular pacing,
especially during the period of reduced VT/VF event rates
on follow-up, cannot be judged from these data. The timing
of individual shocked events, as well as the actuarial presen-
tation of the same over a longer observation period, would
be needed. Another important issue is the management of
concomitant antiarrhythmic therapy and dosing. Informa-
tion on this pivotal issue would assist interpretation of these
findings.
There are data analysis issues. There was significant
attrition from the overall study group with nearly 41% of
patients being unsuitable for paired analysis. The impact of
censored deceased patients in whom event rates may be
quite unequal as well as incomplete data resulting in
elimination of nearly 25% of patients is a significant
concern. In another randomized trial design without cross-
over periods, an intention-to-treat analysis would clearly
have dealt with these patients quite differently. The number
of patients likely to receive ICD therapy is relatively small
due to the modest study cohort and observation period.
Despite this, there was trend toward fewer VT/VF recur-
rences with biventricular pacing. The episode data are
skewed by the large number of events in two patients, both
of which favor the active treatment group. A larger study
population would be important to assess these trends. It is
also unclear if the benefits could be due to the pacing rate or
the dual-site stimulation mode. The absence of a single-site
stimulation cohort or period in the design, as the authors
wisely acknowledge, does not allow assessment of the
benefits of biventricular stimulation mode per se versus rate
support with ventricular pacing at any site. Finally, reduc-
tion in programmed ICD interventions should not be
equated with aborted sudden death.
Alternative approaches to VT/VF prevention. PREVEN-
TION WITH ANTIARRHYTHMIC DRUG THERAPY. With an
increasing availability of large ICD trial databases, statisti-
cally valid analyses of subpopulations are now more feasible.
A recent subgroup analysis indicated that the mortality
benefits of ICD therapy were largely confined to patients
with left ventricular ejection fractions of #35% (25). Mor-
tality benefits conferred by the device may thus be most
prevalent in the patients with a more limited life expectancy
based on cardiac co-morbidity due to markedly impaired left
ventricular function with a possibly lesser likelihood of
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quantitative prolongation of life. Patients with marginally
impaired left ventricular function could obtain comparable
survival benefit with empiric amiodarone therapy with
effective VT/VF prevention. Thus, in certain VT/VF sub-
populations, amiodarone monotherapy may be an accept-
able preventive intervention.
“HYBRID” THERAPY. Recently, combining ICDs and other
antiarrhythmic therapies has been formally examined (26).
Combination or “hybrid” therapy involving different elec-
trical or antiarrhythmic therapies was initiated in the hope
that the drawbacks of ICD shocks can be alleviated. The
introduction of antitachycardia pacing prior to shock deliv-
ery in these devices greatly advanced the cause of reducing
shocks delivered for arrhythmia termination (6). A prospec-
tive controlled trial recently confirmed the benefits of
addition of an antiarrhythmic drug to reduce ICD shocks
received by patients (26). In a controlled crossover trial,
sotalol therapy reduced shock delivery by 63%. Similar
trends are being noted with some newer type 3 agents such
as azimilide (Procter & Gamble, data on file). Observational
studies have also shown the benefit of map-guided trans-
catheter ventricular ablation in reducing shocks in highly
selected patients experiencing cluster shocks for VT storms
(27). Innovations in these individual approaches to widen
their applicability are under active investigation. For exam-
ple, a recent report of linear ventricular ablation lesions in
sinus rhythm could simplify the use of ablation in a “hybrid”
antiarrhythmic therapy algorithm (28).
Conclusions. There are many issues raised by the current
report in the Journal. The major strength of this report from
Higgins et al (6) is its provocative inference that suggests
some merit to clinical evaluation of dual-site stimulation in
a highly symptomatic ventricular tachyarrhythmia popula-
tion. This could extend the potential of the clinical tech-
nique beyond atrial arrhythmias and test fundamental con-
cepts of preventative pacing in different ventricular
arrhythmic substrates. However, the report can only be
considered hypothesis-generating. It should prompt mean-
ingful discussion of an appropriate study design, populations
and end points for dual-site ventricular pacing in the
patients with high risk heart failure and sudden death.
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